

August 23, 2002 Date of Signature



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Hiroto Yoshii

Serial No.

10/081,554

Filed

February 22, 2002

For

PROBE DESIGNING METHOD AND INFORMATION PROCESSING

APPARATUS

Examiner

Unassigned

Art Unit

1645

Assistant Commissioner for Patents Washington, D.C. 20231

BOX MISSING PARTS

Sir:

LETTER CONCERNING NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Enclosed is a copy of the "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures," a paper copy of the "Sequence Listing", a computer readable form copy of the "Sequence Listing" on a disk, a "Statement Regarding Content of Computer Readable Copy of Sequence Listing" and a "Preliminary Amendment" to the above-identified application directing the entry of the "Sequence Listing" into the application. If you have any questions concerning the enclosures or if you require additional information, please do not hesitate to contact me.

Dated: August 23, 2002

Respectfully submitted,

ROBIN, BLECKER & DALEY 330 Madison Avenue New York, New York 10017

T: (212) 682-9640

Marylee Jenkins Reg. No. 37,645 An Attorney of Record

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: August 23, 2002 Assistant Commissioner for Patents, Washington, D.C. 20231, on:

MARYLEE JENKINS

WESTER JENKINS
Signature

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.usplo.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/081,554

02/22/2002

Hiroto Yoshii

B588-027

CONFIRMATION NO. 4281

FORMALITIES LETTER

OC000000008395249

26272 ROBIN BLECKER & DALEY 2ND FLOOR 330 MADISON AVENUE NEW YORK, NY 10017

JUL 1 0 2002

RECEIVED

ROBIN, BLECKER & DALEY

Date Mailed: 07/03/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.


For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE





ent and Trademark Office



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON. D.C. 2023i
www.usddo.gov

RECEIVED

JUL 1 U 2002

Attachment to Notice of Incomplete Reply

ROBIN, BLECKER & DALEY

This is in response to Applicant's remarks regarding sequence rule compliance in the instant application. An application that contains generic techniques to determine DNA sequence information such as DNA molecule length or nucleotide composition, without disclosing specific sequences, would not have to comply with the sequence rules. The instant application, however, also discloses specific sequences. The facts that no sequences are claimed and any specific sequence mentioned would be used solely for illustrative purposes and not represent a novel sequence disclosure are immaterial. Any sequence that is disclosed must be submitted in accordance with 37 CFR 1.821-825. That is the meaning of the "exclusively" language.

Sequences were found at page(s) _____, and/or Figure 3,5,7,8,12